Expand all sections

Nemolizumab

Extended indication Atopic Dermatitis; Prurigo (jeuk)
Therapeutic value No judgement

Product

Active substance Nemolizumab
Domain Chronic immune diseases
Main indication Skin diseases
Extended indication Atopic Dermatitis; Prurigo (jeuk)
Manufacturer Galderma
Route of administration Subcutaneous
Therapeutical formulation Injection

Registration

Registration route Centralised (EMA)
Orphan drug No

Therapeutic value

Therapeutic value No judgement
Frequency of administration 1 times a month
Dosage per administration 0,1-0,5-2,0 mg/kg
References Bron: Ruzicka et al, N Engl J Med. 2017 Mar 2;376(9):826-835. doi: 10.1056/NEJMoa1606490
Additional remarks Toediening 1 maal per 4 weken

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

Cost < 15,000.00
Additional remarks Vergelijkbaar met Dupilumab, zal de concurrentie aan moeten gaan wat de prijs nog zou kunnen drukken.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.